Quasisynchronous Ventricular Tachycardia - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Quasisynchronous Ventricular Tachycardia – A Complete Patient Guide

Quasisynchronous Ventricular Tachycardia (QSVT)

Overview

Quasisynchronous Ventricular Tachycardia (QSVT) is a rare form of ventricular tachyarrhythmia in which the electrical activation of the ventricles occurs almost, but not completely, in synchrony. The term “quasisynchronous” reflects the fact that the ventricular depolarization wavefront is slightly fragmented, producing a narrow‑QRS complex that can be mistaken for supraventricular tachycardia (SVT) on surface ECG.

QSVT most commonly appears in patients with structural heart disease (e.g., ischemic cardiomyopathy, hypertrophic cardiomyopathy) but can also arise in otherwise healthy individuals with genetic channelopathies such as catecholaminergic polymorphic ventricular tachycardia (CPVT) or SCN5A‑related disorders.

  • Age group: Median onset 45–60 years, though cases have been reported in adolescents with inherited arrhythmia syndromes.
  • Gender: Slight male predominance (approximately 1.3 : 1).
  • Prevalence: Exact prevalence is unknown because QSVT is often misdiagnosed as SVT. Current estimates suggest it accounts for < 1 % of all documented ventricular tachycardias in tertiary‑care centers (Mayo Clinic EP Registry, 2022).

Symptoms

The clinical picture of QSVT overlaps with other rapid heart‑rate disorders. Symptoms can be intermittent and vary with the rate and duration of the episode.

Typical presentations

  • Palpitations: A sudden awareness of a fast, “fluttering” heartbeat, often described as racing or pounding.
  • Dizziness or Light‑headedness: Caused by reduced cardiac output.
  • Syncope or Near‑syncope: Transient loss of consciousness, especially during exertion or emotional stress.
  • Chest discomfort: Pressure, tightness, or pain that may mimic angina.
  • Shortness of breath (dyspnea): Particularly when the tachycardia is sustained.
  • Fatigue: Persistent tachycardia can lead to decreased exercise tolerance.
  • Palatal or “thumping” sensation: Patients sometimes feel the thump of the ventricular contraction in the neck.

Atypical or silent presentations

  • Incidental finding on routine ECG or Holter monitoring.
  • Transient ischemic changes on stress testing without angina.
  • Worsening of known heart‑failure symptoms without clear trigger.

Causes and Risk Factors

QSVT is not a single disease; it is a pattern of ventricular activation that can arise from several underlying mechanisms.

Structural heart disease

  • Previous myocardial infarction → scar tissue creates a re‑entrant circuit.
  • Cardiomyopathies (ischemic, dilated, hypertrophic, arrhythmogenic right ventricular cardiomyopathy).
  • Congenital heart defects with postoperative scar (e.g., Tetralogy of Fallot repair).

Genetic/electrophysiological disorders

  • CPVT (RYR2 or CASQ2 mutations).
  • SCN5A loss‑of‑function variants – Brugada syndrome, progressive cardiac conduction disease.
  • Long QT syndrome type 3, where triggered activity can produce a ventricular tachycardia with quasi‑synchronous QRS.

Acquired precipitants

  • Electrolyte disturbances – especially hypokalemia, hypomagnesemia.
  • Acute ischemia or coronary spasm.
  • Drugs that prolong the QT interval or increase catecholamine levels (e.g., certain anti‑psychotics, stimulants, decongestants).
  • Intense physical or emotional stress – common trigger in CPVT‑related QSVT.

Risk‑factor summary

  • Age > 40 years (except in hereditary forms).
  • Male sex.
  • History of myocardial infarction or heart failure.
  • Family history of sudden cardiac death or inherited arrhythmia syndromes.
  • Uncontrolled hypertension, diabetes, or hyperlipidemia – because they accelerate structural disease.
  • Use of QT‑prolonging medication or illicit stimulants.

Diagnosis

Because QSVT mimics SVT, a high index of suspicion and systematic evaluation are essential.

Electrocardiographic clues

  • Rate: Usually 150‑250 bpm.
  • QRS morphology: Narrow (< 120 ms) or borderline; subtle slurring or notching in the terminal portion suggests ventricular origin.
  • AV dissociation: Presence of P waves marching through the QRS complexes (often hidden).
  • Fusion/pendular beats: Intermittent QRS mixing ventricular and supraventricular components.

Diagnostic tests

  1. 12‑lead ECG (baseline and during episode): Capture of an episode is diagnostic; if not present, a rapid‑response monitor may be employed.
  2. Ambulatory monitoring: 24‑hour Holter, event recorder, or 30‑day patch monitor can reveal paroxysmal QSVT.
  3. Exercise stress test: Useful for CPVT‑related QSVT; arrhythmia often appears at 70–85 % of predicted maximal heart rate.
  4. Electrophysiology (EP) study: The gold‑standard. Intracardiac mapping identifies the precise circuit and distinguishes QSVT from SVT with aberrancy.
  5. Cardiac imaging: Echocardiography and cardiac MRI assess structural substrate (scar, fibrosis, hypertrophy).
  6. Laboratory evaluation: Electrolytes, thyroid function, drug screen, and genetic testing when an inherited channelopathy is suspected.

Diagnostic criteria (simplified)

  • Sustained ventricular tachycardia ≥150 bpm lasting >30 seconds or requiring termination.
  • ECG demonstrating narrow or borderline QRS with evidence of AV dissociation or fusion beats.
  • Exclusion of SVT with atrioventricular nodal re‑entry or concealed accessory pathway (confirmed by EP study or adenosine response).

Treatment Options

Treatment aims to terminate the acute episode, prevent recurrence, and address the underlying substrate.

Acute termination

  • IV Adenosine: May transiently block AV conduction; a lack of response suggests ventricular origin.
  • IV Metoprolol or Esmolol: Beta‑blockade is first‑line for rate control, especially in CPVT‑related QSVT.
  • IV Amiodarone: Effective for hemodynamically stable ventricular tachycardia; loading dose 150 mg over 10 min, then infusion.
  • Synchronized cardioversion: Indicated if the patient is unstable (hypotension, chest pain, syncope).

Long‑term rhythm management

  1. Anti‑arrhythmic medications
    • Beta‑blockers (e.g., propranolol 40‑80 mg TID, nadolol 40‑80 mg daily) – cornerstone for CPVT.
    • Class III agents (e.g., sotalol, amiodarone) – used when beta‑blockade insufficient or contraindicated.
    • Flecainide (200‑300 mg daily) – added in CPVT to suppress triggered activity.
  2. Catheter ablation
    • Radiofrequency or cryoablation of the re‑entrant circuit identified during EP study.
    • Success rates 70‑85 % in scar‑related QSVT (Cleveland Clinic data, 2021).
  3. Implantable Cardioverter‑Defibrillator (ICD)
    • Recommended for patients with documented sustained QSVT plus any of the following: prior cardiac arrest, left ventricular ejection fraction ≤35 %, or high‑risk genetic syndrome.
    • Modern sub‑cutaneous ICDs reduce infection risk.
  4. Lifestyle & pharmacologic adjuncts
    • Avoidance of QT‑prolonging drugs (check crediblemeds.org).
    • Strict electrolyte management – maintain K⁺ >4.0 mmol/L, Mg²⁺ >2.0 mg/dL.

Special considerations

  • Pregnant patients: beta‑blockers are generally safe; amiodarone is avoided.
  • Pediatric patients with CPVT: high‑dose propranolol plus flecainide is first‑line; ICD considered after breakthrough events.

Living with Quasisynchronous Ventricular Tachycardia

While QSVT is serious, many individuals lead active lives with proper management.

Self‑monitoring

  • Keep a symptom diary: date, time, activity, heart‑rate (if known), and duration of episodes.
  • Use a validated wearable ECG monitor (e.g., KardiaMobile) to record arrhythmias for your cardiology team.

Medication adherence

  • Take beta‑blockers at the same time each day; set phone reminders.
  • Schedule routine blood tests to monitor amiodarone levels, thyroid, and liver function.

Physical activity

  • Low‑ to moderate‑intensity aerobic exercise (e.g., brisk walking, stationary cycling) is generally safe if heart‑rate does not exceed 80 % of predicted max.
  • Avoid competitive sports, heavy resistance training, and activities that cause abrupt catecholamine surges.

Diet & lifestyle

  • Maintain a low‑sodium, heart‑healthy diet rich in fruits, vegetables, whole grains, and lean protein (DASH pattern).
  • Limit caffeine, energy drinks, and alcohol – all can lower the ventricular threshold.
  • Stay hydrated; dehydration predisposes to electrolyte shifts.

Psychological well‑being

  • Living with an arrhythmia can cause anxiety; cognitive‑behavioral therapy and support groups (e.g., Arrhythmia Alliance) are helpful.
  • Mind‑body techniques like paced breathing or meditation may reduce catecholamine surges.

Prevention

Because QSVT often reflects an underlying disease, prevention focuses on modifying risk factors and early detection.

  • Control cardiovascular risk factors: blood pressure < 130/80 mmHg, LDL‑C < 70 mg/dL for high‑risk patients, HbA1c < 7 % (if diabetic).
  • Regular cardiac screening: Annual ECG and echo for patients with known cardiomyopathy or a family history of sudden cardiac death.
  • Genetic counseling: For individuals with a known channelopathy, cascade testing of first‑degree relatives enables early intervention.
  • Avoid trigger medications: Use drug‑interaction checkers and inform every prescriber of your arrhythmia diagnosis.
  • Electrolyte vigilance: Replace potassium after vomiting/diarrhea; use oral magnesium after intense exercise.

Complications

If left untreated or poorly controlled, QSVT can lead to serious outcomes.

  • Hemodynamic compromise: Sustained rapid rates reduce cardiac output → hypotension, syncope.
  • Sudden Cardiac Death (SCD): Especially in patients with scar‑related re‑entry or genetic channelopathies; annual SCD risk in CPVT ≈ 5‑10 % without therapy.
  • Progression to heart failure: Repeated tachycardia can cause tachy‑cardiomyopathy, lowering ejection fraction.
  • Thromboembolic events: Rare but possible if ventricular stasis occurs during prolonged tachycardia.
  • Medication toxicity: Amiodarone‑induced pulmonary, hepatic, or thyroid dysfunction; requires routine monitoring.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Chest pain that is new, worsening, or radiates to the arm, jaw, or back.
  • Sudden loss of consciousness or near‑syncope.
  • Rapid heartbeat (> 200 bpm) that does not slow with vagal maneuvers or medication.
  • Severe shortness of breath, feeling unable to catch your breath.
  • Profound light‑headedness, confusion, or slurred speech.
  • Signs of heart failure – swelling of ankles, sudden weight gain, or coughing up pink frothy sputum.

These symptoms may indicate a life‑threatening ventricular arrhythmia that requires immediate cardioversion or advanced cardiac life‑support.

References

  • Mayo Clinic. “Ventricular Tachycardia.” Updated 2023. https://www.mayoclinic.org
  • Cleveland Clinic. “Catheter Ablation for Ventricular Tachycardia.” 2021. https://my.clevelandclinic.org
  • American Heart Association. “2023 Guideline for the Management of Patients With Ventricular Arrhythmias.” AHA Journals
  • NIH National Center for Biotechnology Information. “Catecholaminergic Polymorphic Ventricular Tachycardia.” 2022. PMID:35027491
  • World Health Organization. “Sudden Cardiac Death and Arrhythmia.” Fact sheet, 2022. WHO
  • CredibleMeds. “List of QT‑prolonging Drugs.” Updated 2024. https://www.crediblemeds.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References